True Wealth Design LLC Makes New Investment in Natera, Inc. (NASDAQ:NTRA)

True Wealth Design LLC purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 452 shares of the medical research company’s stock, valued at approximately $57,000.

Other institutional investors also recently bought and sold shares of the company. Comerica Bank raised its position in shares of Natera by 458.0% in the 1st quarter. Comerica Bank now owns 14,866 shares of the medical research company’s stock worth $1,360,000 after acquiring an additional 12,202 shares in the last quarter. Cetera Investment Advisers raised its holdings in Natera by 514.9% in the first quarter. Cetera Investment Advisers now owns 19,700 shares of the medical research company’s stock worth $1,802,000 after purchasing an additional 16,496 shares in the last quarter. Cetera Advisors LLC purchased a new position in Natera during the first quarter valued at $442,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Natera during the 1st quarter valued at $83,000. Finally, GAMMA Investing LLC grew its position in shares of Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares during the period. 99.90% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Rowan E. Chapman sold 2,614 shares of Natera stock in a transaction on Friday, September 13th. The shares were sold at an average price of $127.68, for a total transaction of $333,755.52. Following the transaction, the director now owns 7,969 shares in the company, valued at $1,017,481.92. This trade represents a 24.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 256 shares of the business’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the sale, the insider now directly owns 111,891 shares of the company’s stock, valued at approximately $13,434,752.37. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 46,503 shares of company stock valued at $6,325,804 over the last 90 days. Company insiders own 7.60% of the company’s stock.

Natera Stock Performance

Shares of NTRA stock opened at $167.78 on Friday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company has a 50 day moving average price of $135.51 and a 200-day moving average price of $120.32. Natera, Inc. has a 52 week low of $55.56 and a 52 week high of $171.95. The firm has a market capitalization of $22.15 billion, a PE ratio of -95.33 and a beta of 1.53.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm’s revenue was up 63.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.95) EPS. As a group, equities research analysts expect that Natera, Inc. will post -1.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NTRA. BTIG Research boosted their price objective on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Canaccord Genuity Group boosted their price target on Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Morgan Stanley raised their price objective on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Leerink Partners lifted their price objective on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, Craig Hallum increased their target price on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $140.59.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.